462 related articles for article (PubMed ID: 32817336)
21. Nucleic Acid Detection Using CRISPR/Cas Biosensing Technologies.
Aman R; Mahas A; Mahfouz M
ACS Synth Biol; 2020 Jun; 9(6):1226-1233. PubMed ID: 32159950
[TBL] [Abstract][Full Text] [Related]
22. Approaches to study CRISPR RNA biogenesis and the key players involved.
Behler J; Hess WR
Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
[TBL] [Abstract][Full Text] [Related]
23. The engineered single guide RNA structure as a biomarker for gene-editing reagent exposure.
Ryan EC; Huggins LM; Podlevsky JD
Sci Rep; 2023 Jul; 13(1):10804. PubMed ID: 37402738
[TBL] [Abstract][Full Text] [Related]
24. The miniature CRISPR-Cas12m effector binds DNA to block transcription.
Wu WY; Mohanraju P; Liao C; Adiego-Pérez B; Creutzburg SCA; Makarova KS; Keessen K; Lindeboom TA; Khan TS; Prinsen S; Joosten R; Yan WX; Migur A; Laffeber C; Scott DA; Lebbink JHG; Koonin EV; Beisel CL; van der Oost J
Mol Cell; 2022 Dec; 82(23):4487-4502.e7. PubMed ID: 36427491
[TBL] [Abstract][Full Text] [Related]
25. Genome editing using the endogenous type I CRISPR-Cas system in
Hidalgo-Cantabrana C; Goh YJ; Pan M; Sanozky-Dawes R; Barrangou R
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15774-15783. PubMed ID: 31341082
[TBL] [Abstract][Full Text] [Related]
26. The Card1 nuclease provides defence during type III CRISPR immunity.
Rostøl JT; Xie W; Kuryavyi V; Maguin P; Kao K; Froom R; Patel DJ; Marraffini LA
Nature; 2021 Feb; 590(7847):624-629. PubMed ID: 33461211
[TBL] [Abstract][Full Text] [Related]
27. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications.
Pyzocha NK; Chen S
ACS Chem Biol; 2018 Feb; 13(2):347-356. PubMed ID: 29121460
[TBL] [Abstract][Full Text] [Related]
28. The structural biology of CRISPR-Cas systems.
Jiang F; Doudna JA
Curr Opin Struct Biol; 2015 Feb; 30():100-111. PubMed ID: 25723899
[TBL] [Abstract][Full Text] [Related]
29. Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes.
Xu Z; Li Y; Li M; Xiang H; Yan A
Environ Microbiol; 2021 Feb; 23(2):542-558. PubMed ID: 32510745
[TBL] [Abstract][Full Text] [Related]
30. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
Zheng W
Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
[TBL] [Abstract][Full Text] [Related]
31. Origins and evolution of CRISPR-Cas systems.
Koonin EV; Makarova KS
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180087. PubMed ID: 30905284
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review.
Bharathkumar N; Sunil A; Meera P; Aksah S; Kannan M; Saravanan KM; Anand T
Mol Biotechnol; 2022 Apr; 64(4):355-372. PubMed ID: 34741732
[TBL] [Abstract][Full Text] [Related]
33. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.
Kazlauskiene M; Kostiuk G; Venclovas Č; Tamulaitis G; Siksnys V
Science; 2017 Aug; 357(6351):605-609. PubMed ID: 28663439
[TBL] [Abstract][Full Text] [Related]
34. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
Mohanraju P; Makarova KS; Zetsche B; Zhang F; Koonin EV; van der Oost J
Science; 2016 Aug; 353(6299):aad5147. PubMed ID: 27493190
[TBL] [Abstract][Full Text] [Related]
35. Controlling and enhancing CRISPR systems.
Shivram H; Cress BF; Knott GJ; Doudna JA
Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
[TBL] [Abstract][Full Text] [Related]
36. Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum.
Özcan A; Pausch P; Linden A; Wulf A; Schühle K; Heider J; Urlaub H; Heimerl T; Bange G; Randau L
Nat Microbiol; 2019 Jan; 4(1):89-96. PubMed ID: 30397343
[TBL] [Abstract][Full Text] [Related]
37. The immune system of prokaryotes: potential applications and implications for gene editing.
Liu S; Liu H; Wang X; Shi L
Biotechnol J; 2024 Feb; 19(2):e2300352. PubMed ID: 38403433
[TBL] [Abstract][Full Text] [Related]
38. The structural biology of type III CRISPR-Cas systems.
Li X; Han J; Yang J; Zhang H
J Struct Biol; 2024 Mar; 216(1):108070. PubMed ID: 38395113
[TBL] [Abstract][Full Text] [Related]
39. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes.
Koonin EV; Makarova KS
RNA Biol; 2013 May; 10(5):679-86. PubMed ID: 23439366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
